Huaxi Hospital Translational Medicine Complex opened! Will greatly shorten the time from research to clinical transformation.
Cover journalist Ning Zhi
On July 18th, the comprehensive building of translational medicine in Huaxi Hospital, the core base of clinical research in the national major scientific and technological infrastructure of translational medicine (Sichuan), was officially opened.
The reporter learned from the scene that there are currently five national-level facilities for translational medicine in China, and the national major scientific and technological infrastructure for translational medicine (Sichuan) is the second national-level facility for translational medicine after Shanghai, and it is also the first national major scientific and technological infrastructure for biotherapy translational medicine.
Journalist visit
How tall is the translational medicine complex?
In the emergency building of west china hospital, through a corridor, you come to the comprehensive building of translational medicine in Huaxi Hospital. The building is divided into two floors underground and 16 floors above ground, with nearly 200 research beds.
On the morning of the 18th, the reporter first came to the laminar flow research ward on the 16th floor of the translational medicine complex of Huaxi Hospital, where there were all kinds of nurses’ stations and treatment rooms, and several patients who had participated in clinical trials were admitted.
The reporter learned that the laminar flow research ward is jointly built and managed by the Department of Hematology and the National Drug Clinical Research Center to carry out clinical research including autologous, blood/non-blood integration. Zhu Jinbing, chief resident physician of laminar flow ward, said that the main feature of laminar flow ward is aseptic management, which filters out germs and other particles in the air through special filtering devices to create a safe environment for patients participating in clinical trials.
Subsequently, the reporter went to the early clinical research ward on the 15th floor, the precision medicine center on the 7th floor, the information center on the 9th floor, etc. Each floor has cutting-edge equipment and a sense of science and technology. For example, a robot can monitor the humidity and temperature of each cabinet at any time; In the intelligent reference room, the staff only need to input the document number, and the equipment can automatically find out the paper document quickly.
Expert interpretation
Help to introduce more domestic innovative drugs.
Li Weimin, Dean of West China Clinical Medical College/West China Hospital of Sichuan University, said that after the comprehensive building of translational medicine in West China Hospital is put into operation, it will significantly enhance the independent innovation ability of translational medicine research in China and shorten the time from basic research to clinical application by 30-50%; In the next 5-10 years, 50-100 candidate biotherapy products will be supported for transformation.
"Huaxi Hospital attaches great importance to original research, basic research and how to turn basic research into clinical application." Li Weimin said that the opening of the comprehensive building of translational medicine in West China Hospital will further promote the transformation of basic research into clinical application. "China’s drugs are mainly generic drugs, and there are fewer original drugs with independent intellectual property rights. In the future, we will be able to produce more domestic original new drugs by transforming the large facilities of the comprehensive medical building. On the other hand, the price of original new drugs may be lower, thus benefiting more people."
Wei Yuquan, academician of China Academy of Sciences, director of west china hospital Clinical Cancer Center and director of the State Key Laboratory of Biotherapy, said that the comprehensive building of translational medicine in West China Hospital will accelerate the transformation of basic research into clinic and industry. "The bottleneck of our current biomedicine is that basic research and clinical transformation are not closely applied. After the establishment of major facilities, it can speed up the transformation and increase the scale of transformation. "
Frequent highlights
It has three sharp tools to lead the national biotherapy transformation.
The National Major Science and Technology Infrastructure of Translational Medicine (Sichuan) is the largest biotherapy translational medicine research center with the highest comprehensive integration, the most advanced equipment and high openness and sharing in China, and it has three sharp tools to lead the biotherapy transformation in China.
First, the accurate imaging and evaluation service chain runs through the whole process of "basic discovery-clinical research-achievement transformation-industrial development".
As an important part of this chain, the precision imaging center is one of the few clinical imaging research centers in the world that integrates first-class equipment such as 7T magnetic resonance, magnetoencephalography and PET-MRI. Have the research and development ability to lead the international advanced technology. In addition, precision medicine center is the core component of clinical detection module of translational medicine facilities, and it is one of the important strategic development directions of Huaxi Hospital. The center has built three top platforms, namely high-throughput sequencing, single cell sequencing and bioinformatics analysis. It has the most complete and advanced second-generation and third-generation sequencing systems of Illumina, Ion Torrent, Huada and Oxford Nanopore series, 10X Genomics single-cell database building system and high-performance server in the world, mainly carrying out scientific research and clinical testing services based on whole genome, whole exon group and gene panel sequencing. It has undertaken the whole genome sequencing task of a cohort study of 100,000 natural people in West China Hospital. The single detection flux can reach 140 people and the data analysis takes 15 minutes per person. Its sequencing and analysis ability is the first in medical institutions in China, and it has more than 1 million sample resources available for sequencing research.
Second, the national drug clinical trial institution (clinical trial center) is an innovative clinical trial research platform with "one-stop" bags.
As an innovative clinical trial research platform with full functional integration, all-round open sharing and one-stop bag-carrying, the national drug clinical trial institution has 21 full-time research doctors with rich clinical and research experience, 187 special research beds and 4 ICU standard rescue wards. The platform integrates the functions of clinical research ward, follow-up center, integrated management of subjects’ research data, clinical examination, endoscopy, imaging and pathology. Intelligent clinical trial system operation, free inspection, green reservation channel, rapid admission process, professional researcher project implementation, the main implementation links of clinical trials can be completed in the Translational Medicine Building in a "one-stop" manner, thus accelerating the implementation of clinical trial projects. In addition to facing the supporting units, the platform is also open to universities, research institutes, enterprises, hospitals and other institutions to realize the whole society.
Third, the large-scale preparation center of biological agents is a "clinical cell preparation factory".
The large-scale preparation center of biological agents is equipped with a number of the most advanced fully automatic and fully closed cell preparation production lines, and the environment of the core area of cell preparation reaches B+A level. According to the latest industry standards and development trends at home and abroad, it is equipped with a large number of advanced cell production, storage and inspection equipment, such as advanced fully automatic cell processing workstations, fully sealed C+ isolators, large-scale cell extraction and purification systems, liquid nitrogen-free refrigeration systems and flow cell sorters, at a cost of 160 million RMB, reaching the domestic leading level. Mainly aimed at the clinical transformation research of cell therapy, it realizes the preparation, quality control and research and development of various immune cells, including CAR-T, NK (natural killer cells) and umbilical cord blood and mesenchymal stem cells. It is a modern, standardized and large-scale "clinical cell preparation factory".
Transformation case
Huaxi Hospital released two major transformation achievements.
At the launching ceremony, west china hospital released two major transformation achievements.
One originated from the team of Academician Wei Yuquan. The recombinant protein COVID-19 vaccine, developed by the team of Academician Wei Yuquan, is based on the precise design of structural biology, targeting the binding site between novel coronavirus and human cells. By using insect cells to multiply in culture medium, the gene of new coronavirus is introduced into insect cells to produce high-quality recombination vaccines protein. At present, the phase III clinic of the vaccine is cooperating with Japan, Nepal, Kenya, Indonesia, Bahrain, Belarus, Uzbekistan, Mexico and other countries.
The other is from Professor Liu Jin’s team. The team obtained the certificate of Class 1.1 new anesthetic drug and the contract fund of 500 million yuan to start the research and development of skeletal muscle relaxation drugs, and won the "Innovation and Transformation Award" in west china hospital in 2021 respectively. Among them, phosphopropofol disodium for injection was successfully approved as the "Drug Registration Certificate" for Class I new drugs, which is the first new drug certificate with independent intellectual property rights obtained by Huaxi Hospital.
Reporting/feedback